Propionic Acid

Propionic Acid

SCHEMBL2686240

CCC(=O)O.Clc1cccc2c1OCCN2

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.41
HTR1A P08908 2/20 0.37
DRD2 P14416 1/20 0.37
AKR1B1 P15121 3/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
PTGER3 P43115 1/20 0.36
EGFR P00533 3/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
HTR5A P47898 1/20 0.35
AKT1 P31749 1/20 0.35
KMT2A Q03164 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
UBE2N P61088 1/20 0.33
PAX8 Q06710 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31170829 0.85 DRD2 (0.39) NOTUMHTR1ADRD2PTGER3EGFR
Propionic Acid SCHEMBL2687317 0.84 DRD2 (0.40) HTR1ADRD2ADORA2AADORA1AKT1
Propionic Acid SCHEMBL2637824 0.83 ADORA2A (0.45) HTR1ADRD2ADORA2AADORA1AKT1
SCHEMBL9911042 0.77 ADORA2A (0.43) HTR1ADRD2ADORA2AADORA1AKT1
SCHEMBL1246796 0.74 DRD2 (0.36) HTR1ADRD2ADORA2AADORA1AKT1
SCHEMBL1340046 0.73 ALOX5 (0.40) HTR1ADRD2ADORA2AADORA1AKT1
SCHEMBL18665582 0.72 KDM4E (0.43) NOTUMHTR1ADRD2ADORA2AADORA1
SCHEMBL1549847 0.71 ADRA1D (0.43) ADORA2AADORA1AKT1KMT2A
SCHEMBL1612190 0.71 TSHR (0.49) KMT2A
SCHEMBL305910 0.71 ADORA2A (0.46) HTR1ADRD2ADORA2AADORA1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438050-B9 NOVEL DERIVATIVES OF ARYL-{4-HALOGENO-4-[AMINOMETHYL]-PIPERIDIN-1-YL}-METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS PF MEDICAMENT (FR) 2014-04-23 EP disclosed
US-8669250-B2 Derivatives of aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl}-methanone, their method of preparation and their use as medicinal products PIERRE FABRE MEDICAMENT (FR) 2014-03-11 US disclosed
EP-2438050-B1 NOVEL DERIVATIVES OF ARYL-{4-HALOGENO-4-[AMINOMETHYL]-PIPERIDIN-1-YL}-METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS PF MEDICAMENT (FR) 2013-08-07 EP disclosed
US-20120115860-A1 NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS PIERRE FABRE MEDICAMENT (FR) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115860-A1 NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS CYP11B1, CYP11B2, CYP3A43 NOTUM 2647/4885HTR1A 388/4885DRD2 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.